Equities

Profile data is unavailable for this security.

About the company

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

  • Revenue in USD (TTM)25.13bn
  • Net income in USD1.98bn
  • Incorporated1900
  • Employees75.00k
  • Location
    Abbott Laboratories100 Abbott Park RdABBOTT PARK 60064-3500United StatesUSA
  • Phone+1 (847) 937-6100
  • Websitehttp://www.abbott.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Allergan plc15.48bn-7.55bn58.14bn16.70k--0.8779--3.76-22.57-22.5045.52213.950.11792.575.95926,880.30-5.53-2.30-5.91-2.5186.6571.93-46.93-16.641.08-0.66980.2989--14.8426.0261.62--18.05--
Biogen Inc11.84bn3.49bn66.40bn7.40k19.255.2714.275.6116.3116.3155.2659.570.52411.496.141,599,851.0015.4218.8417.7622.0387.3488.0729.4330.481.9019.900.33630.006.3617.794.3924.5823.61--
Celgene Corporation12.50bn3.45bn81.37bn7.13k24.358.2619.296.514.244.2415.4212.510.42740.87197.351,752,734.0011.809.6213.3210.8496.3695.3127.6021.193.529.770.43510.0021.3218.3224.798.6912.32--
Eli Lilly and Co22.47bn2.22bn91.88bn41.98k39.736.1724.674.092.102.1021.2313.530.55761.435.04535,344.905.529.187.4712.3273.6976.229.9015.311.0370.190.473765.616.33-2.6613.67-8.84-8.400.8033
Gilead Sciences, Inc.27.48bn11.60bn94.56bn9.00k8.243.817.413.448.798.7920.8119.010.45322.755.983,053,111.0019.1029.4523.2336.9884.7584.0242.1445.293.5622.620.53688.82-6.8929.37-25.4436.9441.49--
Abbott Laboratories25.13bn1.98bn96.67bn75.00k45.793.0221.583.851.211.2914.9718.400.44993.736.19335,120.003.553.064.163.9054.7155.067.897.602.263.380.4272105.402.20-0.523-59.21-1.14-5.54-11.17
Bristol-Myers Squibb Co20.57bn4.23bn101.26bn25.00k24.346.8520.174.922.542.5412.379.030.60774.135.05822,800.0012.417.6417.1610.4072.5974.6620.4315.431.46--0.361596.4717.31-1.77184.793.7927.052.71
Amgen, Inc.23.01bn8.18bn123.96bn19.20k15.423.8512.105.3911.0711.0731.1644.360.29041.456.981,198,542.0010.329.0211.7010.3082.2880.7735.5429.055.7218.520.526135.466.148.0911.2815.968.1048.17
Data as of Nov 17 2017. Currency figures normalised to Abbott Laboratories's reporting currency: US Dollar USD

Institutional shareholders

29.91%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2017126.85m7.30%
SSgA Funds Management, Inc.as of 30 Jun 201776.96m4.43%
BlackRock Fund Advisorsas of 30 Jun 201775.65m4.35%
Massachusetts Financial Services Co.as of 30 Jun 201754.19m3.12%
Wellington Management Co. LLPas of 30 Jun 201748.19m2.77%
Capital Research & Management Co. (Global Investors)as of 30 Jun 201747.59m2.74%
T. Rowe Price Associates, Inc.as of 30 Jun 201729.06m1.67%
Northern Trust Investments, Inc.as of 30 Jun 201726.87m1.55%
Norges Bank Investment Managementas of 31 Dec 201617.40m1.00%
Geode Capital Management LLCas of 30 Jun 201716.84m0.97%
More ▼
Data from 31 Dec 2016 - 30 Jun 2017Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.